US-based clinical research services provider Science 37 closed a $6.5m series A round on Tuesday co-led by dRx Capital, the joint venture between semiconductor technology producer Qualcomm and pharmaceutical firm Novartis.
The round was co-led with venture capital firm Lux Capital. Science 37 has not disclosed details of any seed funding.
Science 37 uses mobile engagement and locally-delivered medical services to make clinical testing more efficient. It will use the funding to develop and roll out its operating model.
Lucian Iancovici, an investment manager at Qualcomm unit Qualcomm Ventures that also works with dRx Capital, said: “Science 37 is the kind of disruptive innovator we are looking for as an investment opportunity.
“The company is at the heart of the digital revolution in healthcare and is fundamentally rethinking the clinical trial experience and research operations for the benefit of patients. Science 37 is an important new tool to accelerate the development of new drugs and devices across the entire pharmaceutical industry.”